Derek Gallacher

Corporate Officer/Principal at Javelin Pharmaceuticals, Inc.

Health Technology

Profile

Derek Gallacher is a Managing Director of European for Javelin Pharmaceuticals, Inc. He was Director of European Analgesic Marketing and European Marketing Director for Mundipharma International Ltd.
Mr. Gallacher has 20 years of pharmaceutical experience.
Previously, he worked with Beecham and Glaxo Pharmaceuticals and Napp Pharmaceuticals Ltd.

Derek Gallacher active positions

Companies	Position	Start
Javelin Pharmaceuticals, Inc. Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.	Corporate Officer/Principal	-

All active positions of Derek Gallacher

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Derek Gallacher's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Javelin Pharmaceuticals, Inc. Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.	Health Technology